Amgen Inc. $AMGN Stock Holdings Increased by NEOS Investment Management LLC

NEOS Investment Management LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 48.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 229,434 shares of the medical research company’s stock after purchasing an additional 74,877 shares during the quarter. NEOS Investment Management LLC’s holdings in Amgen were worth $64,746,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Sequoia Financial Advisors LLC lifted its stake in Amgen by 2.3% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after acquiring an additional 3,619 shares in the last quarter. Atlantic Union Bankshares Corp increased its holdings in shares of Amgen by 165.0% in the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after purchasing an additional 6,627 shares during the period. Davis Capital Management purchased a new stake in shares of Amgen in the third quarter worth approximately $1,841,000. D.A. Davidson & CO. boosted its holdings in shares of Amgen by 2.6% during the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after purchasing an additional 6,222 shares during the period. Finally, Global Wealth Management Investment Advisory Inc. grew its position in Amgen by 56.2% during the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after purchasing an additional 4,699 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.69% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on AMGN. The Goldman Sachs Group increased their target price on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Wall Street Zen lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 7th. Leerink Partners lifted their price objective on Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft upped their target price on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. Finally, Piper Sandler raised their price target on Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a research note on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $354.04.

Amgen Trading Up 0.8%

Shares of AMGN stock opened at $369.19 on Tuesday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $385.12. The company has a market cap of $198.80 billion, a PE ratio of 25.94, a price-to-earnings-growth ratio of 3.78 and a beta of 0.46. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The business’s 50 day moving average is $338.43 and its two-hundred day moving average is $314.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the previous year, the company earned $5.31 earnings per share. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.